Oruka Therapeutics, Inc. — 2024 Q1 Filing Summary
Filing identity: The supplied filing is ARCA biopharma, Inc.’s Form 10-Q for the quarter ended March 31, 2024, not a 10-Q filed by Oruka Therapeutics, Inc. The filing discusses Oruka because ARCA agreed to merge with it after quarter-end.
Business context and reporting period
ARCA is a clinical-stage biopharmaceutical company with no product revenue. Its lead candidate is Gencaro for atrial fibrillation in certain heart-failure patients; it also holds rights to rNAPc2, for which it does not currently plan further clinical development absent a partner. The reported period is the three months ended March 31, 2024, compared with the three months ended March 31, 2023.
Financial performance and liquidity
| Metric | Q1 2024 | Q1 2023 or comparison |
|---|---|---|
| Revenue | None to date | None to date |
| General and administrative expense | $2.317 million | $1.406 million |
| Research and development expense | $165,000 | $390,000 |
| Total expenses / operating loss | $2.482 million | $1.796 million |
| Interest and other income | $473,000 | $450,000 |
| Net loss | $2.009 million | $1.346 million |
| Basic and diluted loss per share | $0.14 | $0.09 |
| Operating cash used | $1.528 million | $1.595 million |
| Cash and cash equivalents | $35.903 million at March 31, 2024 | $37.431 million at December 31, 2023 |
| Total liabilities | $1.581 million | $841,000 at December 31, 2023 |
| Stockholders’ equity | $35.125 million | $37.020 million at December 31, 2023 |
There were no investing or financing cash flows in either quarter. The filing reports no interest expense or funded debt; liabilities were primarily accounts payable, accruals and lease obligations. Profit margins are not meaningful because the company generated no revenue.
Material changes versus prior period
- Net loss increased by $663,000 year over year. G&A rose $911,000, primarily due to approximately $1.1 million of additional professional fees related to the proposed merger, partly offset by lower personnel and termination-related costs.
- R&D expense declined $225,000, reflecting reduced headcount and no Q1 2024 expense for the former CEO’s academic research grant.
- Cash declined $1.528 million from year-end 2023, principally from operating activities. Accrued expenses and other liabilities rose to $968,000 from $175,000.
Outlook, transaction, and risks
- Management estimated that March 31 cash would fund operations through the middle of fiscal 2025. Additional capital would be needed for a Phase 3 Gencaro trial; the company warned that it may have to reduce or discontinue activities if financing or a strategic transaction is unavailable.
- On April 3, 2024, ARCA and Oruka entered into a merger agreement. Oruka securityholders were expected to own approximately 97.62% of the combined company and pre-merger ARCA holders approximately 2.38%, subject to assumptions and transaction adjustments. ARCA’s net cash below $5 million could increase the shares issued to Oruka holders. ARCA expected to declare a pre-merger cash dividend for ARCA holders for net cash exceeding $5 million; the amount was not yet determined.
- Oruka investors agreed to provide approximately $275 million in pre-closing financing, subject to transaction conditions. Merger closing conditions include required stockholder approvals, Nasdaq listing approval, an effective registration statement, and financing agreements providing for at least $175 million in proceeds. The merger was not assured of completion; specified termination circumstances could trigger a $440,000 fee.
- Management expected higher 2024 G&A expense from merger and strategic-review costs, and lower R&D expense while strategic alternatives are explored. Further clinical development could increase R&D costs substantially.
- Key risks include merger failure or delay, limited cash runway, inability to raise capital, Nasdaq listing compliance, clinical and regulatory uncertainty, and the possibility of dissolution and liquidation if strategic alternatives fail. The filing also reports that the FDA Special Protocol Assessment for a planned Gencaro Phase 3 trial does not guarantee approval.
- After quarter-end, CEO Michael Bristow separated from the company, Thomas Keuer became president and principal executive officer, and retention bonuses for two executives were increased. These events are subsequent to the reporting date.
Important facts for investors to verify
- Confirm merger status, approval and listing conditions, financing proceeds, closing timing, and the final ownership and exchange-ratio calculations.
- Verify ARCA’s net cash at closing, any special dividend amount, and the implications if net cash is below $5 million.
- Track cash burn, merger-related expenses, and whether the stated mid-2025 runway remains realistic.
- Assess whether Gencaro development will continue and how it will be funded; verify whether any partner is secured for rNAPc2.
- Monitor Nasdaq listing compliance and any changes to the company’s liquidity, capital needs, or plans if the merger does not close.